SCHEMBL308743

SCHEMBL308743

CCOC(=O)c1cc(OCC)c2c(c1)c(Cl)cn2C1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
GLA P06280 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
NOTUM Q6P988 1/20 0.36
ADRB2 P07550 1/20 0.36
BAZ2B Q9UIF8 1/20 0.36
BAZ2A Q9UIF9 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL308549 0.75 GLA (0.41) ALDH1A1GLACA12CA1CA2
SCHEMBL309253 0.75 HSD17B2 (0.42) ALDH1A1CA12CA1CA2CA7
SCHEMBL4782659 0.74 GLA (0.38) ALDH1A1GLACA12CA1CA2
SCHEMBL1121570 0.71 CA12 (0.55) ALDH1A1CA12CA1CA2CA7
SCHEMBL308973 0.71 TSHR (0.39) ALDH1A1GLACA12CA1CA2
SCHEMBL308796 0.70 RXFP1 (0.38) ALDH1A1GLACA12CA1CA2
SCHEMBL309447 0.69 GLA (0.34) ALDH1A1GLACA12CA1CA2
SCHEMBL27185252 0.69 ACACA (0.47) ALDH1A1CA12CA1CA2CA7
SCHEMBL308949 0.68 HSD17B2 (0.48) ALDH1A1CA12CA1CA2CA7
SCHEMBL16056528 0.68 HTT (0.49) ALDH1A1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2111406-B1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS MERCK SHARP & DOHME (US) 2012-10-24 EP disclosed
US-8093389-B2 e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases MERCK SHARP & DOHME CORP. (US) 2012-01-10 US disclosed
US-20080171761-A1 Substituted spirochromanone derivatives MERCK SHARP & DOHME LLC 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171761-A1 Substituted spirochromanone derivatives CBR3, CBR1, CNKSR1 ALDH1A1 901/4885GLA 4195/4885CA12 3210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.